A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Andreas Moraitis, MD
Corcept Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
45 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site 25
Vienna, State of Vienna, Austria
- Site 22
Sofia, Bulgaria
- Site 50
Munich, Bavaria, Germany
- Site 46
Würzburg, Germany
- Site 32
Ramat Gan, Israel
- Site 23
Tel Aviv, Israel
- Site 40
Milan, Milano, Italy
- Site 31
Rome, Roma, Italy
- Site 43
Orbassano, Torino, Italy
- Site 34
Milan, Italy
- Site 28
Naples, Italy
- Site 51
Padova, Italy
- Site 37
Rome, Italy
- Site 52
Torino, Italy
- Site 48
Gliwice, Poland
- Site 47
Krakow, Poland
- Site 35
Lublin, Poland
- Site 38
Bucharest, Romania
- Site 41
Bucharest, Romania
- Site 42
Bucharest, Romania
- Site 14
Málaga, Spain
- Site 13
Seville, Spain
- Site 26
Valencia, Spain
- Site 27
Birmingham, Alabama, United States
- Site 17
Stanford, California, United States
- Site 53
Torrance, California, United States
- Site 07
Atlanta, Georgia, United States
- Site 16
Indianapolis, Indiana, United States
- Site 09
Metairie, Louisiana, United States
- Site 36
Baltimore, Maryland, United States
- Site 11
Fall River, Massachusetts, United States
- Site 33
Rochester, Minnesota, United States
- Site 06
Jackson, Mississippi, United States
- Site 54
Reno, Nevada, United States
- Site 10
Jamaica, New York, United States
- Site 44
New York, New York, United States
- Site 01
Wilmington, North Carolina, United States
- Site 30
Cleveland, Ohio, United States
- Site 21
Columbus, Ohio, United States
- Site 02
Summerville, South Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Jul 2020
- Primary completion
- 19 Sept 2024
- Completion
- 19 Sept 2024
- Last update posted
- 4 Sept 2025
- Registered enrollment
- 137
- Registry id
- NCT04308590
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.